Given the downregulation of Myd88 in preleukemic cells under antibiotic treatment as well as in Pax5+/− B-ALL blasts, we next directly tested the requirement for Myd88 in B-ALL development. This evidence concerns the gene MYD88 and precursor B-cell acute lymphoblastic leukemia.